JP2018527372A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527372A5
JP2018527372A5 JP2018513780A JP2018513780A JP2018527372A5 JP 2018527372 A5 JP2018527372 A5 JP 2018527372A5 JP 2018513780 A JP2018513780 A JP 2018513780A JP 2018513780 A JP2018513780 A JP 2018513780A JP 2018527372 A5 JP2018527372 A5 JP 2018527372A5
Authority
JP
Japan
Prior art keywords
substituted
compound
alkoxy
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527372A (ja
JP6966428B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052144 external-priority patent/WO2017049091A1/en
Publication of JP2018527372A publication Critical patent/JP2018527372A/ja
Publication of JP2018527372A5 publication Critical patent/JP2018527372A5/ja
Application granted granted Critical
Publication of JP6966428B2 publication Critical patent/JP6966428B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513780A 2015-09-16 2016-09-16 副溝結合テイルを有するdna結合物質 Expired - Fee Related JP6966428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219380P 2015-09-16 2015-09-16
US62/219,380 2015-09-16
PCT/US2016/052144 WO2017049091A1 (en) 2015-09-16 2016-09-16 Dna binding agents with a minor groove binding tail

Publications (3)

Publication Number Publication Date
JP2018527372A JP2018527372A (ja) 2018-09-20
JP2018527372A5 true JP2018527372A5 (enExample) 2019-10-24
JP6966428B2 JP6966428B2 (ja) 2021-11-17

Family

ID=58289623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513780A Expired - Fee Related JP6966428B2 (ja) 2015-09-16 2016-09-16 副溝結合テイルを有するdna結合物質

Country Status (7)

Country Link
US (1) US10358439B2 (enExample)
EP (1) EP3350145B1 (enExample)
JP (1) JP6966428B2 (enExample)
CN (1) CN108368006B (enExample)
AU (1) AU2016323777B2 (enExample)
PL (1) PL3350145T3 (enExample)
WO (1) WO2017049091A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4433039A4 (en) * 2021-11-17 2025-10-29 Univ Texas WATER-SOLUBLE SALTS OF DNA-BINDING AGENTS
WO2026026748A1 (zh) * 2024-07-30 2026-02-05 上海齐鲁制药研究中心有限公司 蒽环类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288608A (en) * 1978-06-01 1981-09-08 Research Corporation Synthesis of anthracyclines
US4196127A (en) * 1978-06-01 1980-04-01 Research Corporation Anthracyclines
CA1174669A (en) * 1980-07-18 1984-09-18 Michael J. Broadhurst Anthracycline glycosides
ZA814722B (en) * 1980-07-18 1982-07-28 Hoffmann La Roche Novel anthracycline glycosides
CA2249593A1 (en) * 1996-03-22 1997-09-25 Waldemar Priebe Bis-anthracyclines with high activity against doxorubicin resistant tumors
GB9812937D0 (en) * 1998-06-16 1998-08-12 Btg Int Ltd Compounds
WO2000056267A2 (en) 1999-03-19 2000-09-28 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
AU2003217782A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Representated By The Secretary, Deparment Of Health Dna-binding polyamide drug conjugates
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
SE0401066D0 (sv) * 2004-04-22 2004-04-22 Stefan Sjoeberg Chemical Derivatives
PL380561A1 (pl) * 2006-09-05 2008-03-17 Szeja Wiesław Prochem Szeja Sposób otrzymywania pochodnych antracyklin
AU2010223045A1 (en) * 2009-03-12 2011-11-03 Luitpold Pharmaceuticals, Inc. GABA-linked anthracycline-lipid conjugates

Similar Documents

Publication Publication Date Title
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
RU2014153800A (ru) Соединения 5-азаиндазола и способы их применения
JP2019519503A5 (enExample)
RU2014106966A (ru) Пиразоло[3,4-с]пиридины и способы их применения
JP2020508310A5 (enExample)
JP2015520753A5 (enExample)
RS52274B2 (sr) Jedinjenje diarilhidantoina
JP2013535437A5 (enExample)
JP2010524957A5 (enExample)
JP2018513832A5 (enExample)
JPWO2014157444A1 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2014532751A5 (enExample)
WO2016014390A1 (en) Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
RU2015114967A (ru) Производные ингенола, применяемые для лечения рака
CN103965175B (zh) 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用
RU2010150964A (ru) Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам
JP2020518649A5 (enExample)
RU2004135307A (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
JP2013525290A5 (enExample)
RU2016116915A (ru) Комбинация
JP2010500971A5 (enExample)
RU2016137761A (ru) Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения
RU2010120810A (ru) Гидратированные кристаллические сложные эфиры камптотецина для лечения рака
ES2286280T3 (es) Utilizacion de sustancias activas con un efecto agonista de receptores nu de opiodes y con un efecto antagonista de receptores de opiodes, como medicamentos combinados para el tratamiento de un cancer.
JP2011514356A5 (enExample)